Stiller C A, Eatock E M
Childhood Cancer Research Group, Department of Paediatrics, University of Oxford, 57 Woodstock Road, Oxford OX2 6HJ, UK.
Arch Dis Child. 1999 Sep;81(3):202-8. doi: 10.1136/adc.81.3.202.
To document survival rates after acute lymphoblastic leukaemia (ALL) during the era of modern chemotherapy, to assess effects of prognostic factors at presentation, and to investigate the relation of survival to patterns of organisation of care.
From a population based series of 5078 children diagnosed in the UK during 1980-94, 4988 remained for analysis after exclusion of nine children ascertained from death certificates alone and 81 who received no antileukaemia treatment.
Actuarial survival rates.
Between 1980-84 and 1990-94, the proportion of children treated at paediatric oncology centres rose from 77% to 89%, and the proportion entered into national trials rose from 59% to 82%. Each of age, sex, white blood count, immunophenotype, and Down's syndrome status had a highly significant effect on survival. Five year survival improved from 67% in 1980-84 to 81% in 1990-94, a 42% reduction in the risk of death within five years of diagnosis. Survival did not differ significantly between hospitals with different numbers of new patients per year or between paediatric oncology centres and other hospitals. Children who were entered into national trials had higher survival and this difference became greater in recent years; five year survival rates for children diagnosed during 1980-84 were 70% and 64% for trial and non-trial patients, respectively; in 1990-94 the rates were 84% and 68% for trial and non-trial patients, respectively.
Survival after ALL continues to improve. Nearly 50 children/year diagnosed during 1990-94 survived who would have died a decade before. Survival does not vary systematically with place of treatment but is higher for children entered into national trials.
记录现代化疗时代急性淋巴细胞白血病(ALL)后的生存率,评估初诊时预后因素的影响,并研究生存率与护理组织模式之间的关系。
在1980 - 1994年期间,从英国确诊的5078例儿童的人群系列中,排除仅从死亡证明确定的9例儿童和未接受抗白血病治疗的81例儿童后,剩余4988例用于分析。
精算生存率。
在1980 - 1984年和1990 - 1994年期间,在儿科肿瘤中心接受治疗的儿童比例从77%上升至89%,进入全国试验的比例从59%上升至82%。年龄、性别、白细胞计数、免疫表型和唐氏综合征状态中的每一项对生存率都有高度显著的影响。五年生存率从1980 - 1984年的67%提高到1990 - 1994年的81%,诊断后五年内死亡风险降低了42%。每年新患者数量不同的医院之间或儿科肿瘤中心与其他医院之间的生存率没有显著差异。进入全国试验的儿童生存率更高,且近年来这种差异变得更大;1980 - 1984年期间确诊的儿童,试验组和非试验组的五年生存率分别为70%和64%;1990 - 1994年,试验组和非试验组的五年生存率分别为84%和68%。
ALL后的生存率持续提高。在1990 - 1994年期间每年确诊的近50例儿童存活下来,而在十年前他们可能会死亡。生存率不会因治疗地点而有系统性差异,但进入全国试验的儿童生存率更高。